The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
Shashwat Goenka takes over as Vice President of industry body
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Mumbai event on June 24–25 will spotlight real-world impact of pharmacovigilance beyond AI adoption
The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
NEJM study shows strong protection across strains
Hair care & quick commerce shine
Approval strengthens the company’s growing international anti-infective portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
